Replies to post #66880 on Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

I suspect we`re all correct that the hold is delaying the finalization of an Axal deal. Or it was basically done,with some minor changes possibly needed,and then the hold interrupted it being inked. Now Ken will get the credit for it getting the hold removed,and then the credit for the deal and the share price correction to the upside. One could say that Sidransky did Ken a big solid favor by giving him this opportunity to change his rep from recent loser to big winner. Considering what a winner CEO is worth to Wall Street,Ken could write his own ticket after turning Adxs around,which might`ve been already slated by Tony and the BOD prior to his arrival,at least that`s what I think is about to finally be made known to all in the next several weeks.

[island man]

Yeah he did give himself some cheapo shares

[ubmmg]

Tony didn't sit around for 10 months twiddling his thumbs..

How do you know? Do you work at Advaxis? Or, just speculating as everyone else on this board?
So far, all indicators point toward the fact that Tony's tenure has been a colossal failure and the company's future has been gravely jeopardized due to lack of leadership at Advaxis for 10+ months. He was full of hot air trying to sell a concept of a four piece pie, and failed miserably. Not sure what skill sets he had, not science of course, but even his public speaking skills were lacking. Business acumen? Give me a break. He was supposed to cut a cash burn rate, but it's been almost flat at the unsustainable levels: too high burn rate which is border line irresponsible. This is what forced them to dilute at $2. What about a workforce reduction? How about not demanding a pay increase? RSUs and options? Too long a list to provide, you all know that.
Some expect that once the hold is lifted we gap up to $2 or even $3 and then onto the races. I would temper my expectations and caution everyone that we likely will see no bump in the share price, or it'd be a temporary spike and fade. We need a strong catalyst that involves either a good/great clinical data, and/or a cash infusion by a deal or partnership. Not sure what to expect with the PSA data at ASCO, we should see full abstracts in less than two weeks, but hope it'll be good. As for the theories that Tony has been close to a deal and left that deal to KB to take a victory lap, I would not subscribe to that assumption. Until I see the fruits of that behind the scenes work, I'm skeptical. For now. We shall see what KB will do in few weeks. Until then, I'm holding, not buying. They need to show me (not just me) that there's a new reason to be optimistic about Advaxis.
@wmtgreeter